NRG-GI004
Closed to Accrual
Protocol Information
Tab containing protocol details, study design, and eligibility criteria
Tab containing study documents, informed consent forms, and study materials
Tab containing information for potential study participants
Colorectal Cancer Metastatic dMMR/MSI-H Immuno-Therapy (COMMIT) Study: A Randomized Phase III Study of mFOLFOX6/Bevacizumab/Atezolizumab Combination Versus Single Agent Atezolizumab in the First-Line Treatment of Patients with Deficient DNA Mismatch Repair (dMMR)/Microsatellite Instability-High (MSI-H) Metastatic Colorectal Cancer
Status
Closed to Accrual
Open to Accrual
November 7, 2017
Temporarily Closed to Accrual
June 4, 2020
Open to Accrual
January 29, 2021
Temporarily Closed to Accrual
March 31, 2025
Closed to Accrual
September 2, 2025
Disease Site
Brain [BN] Other
Phase
III
Developmental Therapeutics
Yes
Target Accrual
347
Protocol Documents
Available via the National Cancer Institute (NCI) Cancer Trials Support Unit (CTSU) website.
Patient Study Webpage
There is no available patient study webpage available for this trial at this time.
-
Share this study.
-
-
-
-
